STEM CELL THERAPEUTI Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Article By: The Life Sciences Report
Thursday, February 12, 2015 5:59 PM EST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well.
In this article: NBI, BMY, MRK, RHHBY, ENDP, TRIL
Being Early On An Early Asset: Trillium May Be A Diamond In The Rough Immunotherapy Stock
Article By: Jake King
Wednesday, October 29, 2014 9:59 AM EST
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
In this article: TRIL, CELG


Latest Tweets for $TRIL

No tweets yet!